Differential prognostic impact of stratified additional chromosome abnormalities on disease progression among Malaysian chronic myeloid leukemia patients undergoing treatment with imatinib mesylate

被引:2
作者
Siti Mariam, Ismail [1 ]
Norhidayah, Ramli [1 ]
Zulaikha, Abu Bakar [1 ]
Nazihah, Mohd Yunus [1 ]
Rosline, Hassan [2 ]
Kausar, Ghazali Anis [3 ]
Sarina, Sulong [1 ]
Azlan, Husin [4 ]
Ankathil, Ravindran [1 ]
机构
[1] Univ Sains Malaysia, Human Genome Ctr, Sch Med Sci, Kubang Kerian, Kelantan, Malaysia
[2] Univ Sains Malaysia, Sch Med Sci, Dept Haematol, Kubang Kerian, Kelantan, Malaysia
[3] Univ Sains Malaysia, Sch Med Sci, Unit Biostat & Res Methodol, Kubang Kerian, Kelantan, Malaysia
[4] Univ Sains Malaysia, Sch Med Sci, Internal Med, Kubang Kerian, Kelantan, Malaysia
来源
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
关键词
chronic myeloid leukemia; additional chromosome abnormalities (ACAs); disease progression; imatinib mesylate; resistance; stratification; CHRONIC MYELOGENOUS LEUKEMIA; GIMEMA WORKING PARTY; BLAST CRISIS; CYTOGENETIC RESPONSES; GENE-EXPRESSION; FOLLOW-UP; RESISTANCE; CELLS; CML; P53;
D O I
10.3389/fonc.2022.720845
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The emergence of additional chromosome abnormalities (ACAs) in chronic myeloid leukemia (CML) patients during treatment with a tyrosine kinase inhibitor (TKI) regime is generally associated with resistance to treatment and a sign of disease progression to accelerated phase or blast phase. We report the type, frequency, and differential prognostic impact of stratified ACAs with treatment response in 251 Malaysian CML patients undergoing TKI therapy. ACAs were observed in 40 patients (15.9%) of which 7 patients (17.5%) showed ACAs at time of initial diagnosis whereas 33 patients (82.5%) showed ACAs during the course of IM treatment. In order to assess the prognostic significance, we stratified the CML patients with ACAs into four groups, group 1 (+8/+Ph), group 2 (hypodiploidy), group 3 (structural/complex abnormalities); group 4 (high-risk complex abnormalities), and followed up the disease outcome of patients. Group 1 and group 2 relatively showed good prognosis while patients in group 3 and group 4 had progressed or transformed to AP or blast phase with a median survival rate of 12 months after progression. Novel ACAs consisting of rearrangements involving chromosome 11 and chromosome 12 were found to lead to myeloid BP while ACAs involving the deletion of 7q or monosomy 7 led toward a lymphoid blast phase. There was no evidence of group 2 abnormalities (hypodiploidy) contributing to disease progression. Compared to group 1 abnormalities, CML patients with group 3 and group 4 abnormalities showed a higher risk for disease progression. We conclude that the stratification based on individual ACAs has a differential prognostic impact and might be a potential novel risk predictive system to prognosticate and guide the treatment of CML patients at diagnosis and during treatment.
引用
收藏
页数:16
相关论文
共 89 条
[1]   ETV6-LPXN Fusion Transcript Generated by t(11;12)(q12.1;p13) in a Patient With Relapsing Acute Myeloid Leukemia With NUP98-HOXA9 [J].
Abe, Akihiro ;
Yamamoto, Yukiya ;
Iba, Sachiko ;
Kanie, Tadaharu ;
Okamoto, Akinao ;
Tokuda, Masutaka ;
Inaguma, Yoko ;
Yanada, Masamitsu ;
Morishima, Satoko ;
Mizuta, Shuichi ;
Akatsuka, Yoshiki ;
Okamoto, Masataka ;
Kameyama, Toshiki ;
Mayeda, Akila ;
Emi, Nobuhiko .
GENES CHROMOSOMES & CANCER, 2016, 55 (03) :242-250
[2]  
[Anonymous], 2003, CANC CYTOGENETICS ME
[3]   The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [J].
Arber, Daniel A. ;
Orazi, Attilio ;
Hasserjian, Robert ;
Thiele, Jurgen ;
Borowitz, Michael J. ;
Le Beau, Michelle M. ;
Bloomfield, Clara D. ;
Cazzola, Mario ;
Vardiman, James W. .
BLOOD, 2016, 127 (20) :2391-2405
[4]   Chronic myeloid leukemia in Asia [J].
Au, Wing Y. ;
Caguioa, Priscilla B. ;
Chuah, Charles ;
Hsu, Szu Chun ;
Jootar, Saengsuree ;
Kim, Dong-Wook ;
Kweon, Il-Young ;
O'Neil, William M. ;
Saikia, Tapan K. ;
Wang, Jianxiang .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2009, 89 (01) :14-23
[5]   A review of the European LeukemiaNet recommendations for the management of CML [J].
Baccarani, Michele ;
Castagnetti, Fausto ;
Gugliotta, Gabriele ;
Rosti, Gianantonio .
ANNALS OF HEMATOLOGY, 2015, 94 :S141-S147
[6]   European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 [J].
Baccarani, Michele ;
Deininger, Michael W. ;
Rosti, Gianantonio ;
Hochhaus, Andreas ;
Soverini, Simona ;
Apperley, Jane F. ;
Cervantes, Francisco ;
Clark, Richard E. ;
Cortes, Jorge E. ;
Guilhot, Francois ;
Hjorth-Hansen, Henrik ;
Hughes, Timothy P. ;
Kantarjian, Hagop M. ;
Kim, Dong-Wook ;
Larson, Richard A. ;
Lipton, Jeffrey H. ;
Mahon, Francois-Xavier ;
Martinelli, Giovanni ;
Mayer, Jiri ;
Mueller, Martin C. ;
Niederwieser, Dietger ;
Pane, Fabrizio ;
Radich, Jerald P. ;
Rousselot, Philippe ;
Saglio, Giuseppe ;
Saussele, Susanne ;
Schiffer, Charles ;
Silver, Richard ;
Simonsson, Bengt ;
Steegmann, Juan-Luis ;
Goldman, John M. ;
Hehlmann, Ruediger .
BLOOD, 2013, 122 (06) :872-884
[7]   Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update [J].
Bavaro, Luana ;
Martelli, Margherita ;
Cavo, Michele ;
Soverini, Simona .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (24)
[8]   BCR-ABL-MEDIATED INHIBITION OF APOPTOSIS WITH DELAY OF G2/M TRANSITION AFTER DNA-DAMAGE - A MECHANISM OF RESISTANCE TO MULTIPLE ANTICANCER AGENTS [J].
BEDI, A ;
BARBER, JP ;
BEDI, GC ;
ELDEIRY, WS ;
SIDRANSKY, D ;
VALA, MS ;
AKHTAR, AJ ;
HILTON, J ;
JONES, RJ .
BLOOD, 1995, 86 (03) :1148-1158
[9]  
BI SC, 1994, EXP HEMATOL, V22, P95
[10]   MOLECULAR CHARACTERISTICS OF CHRONIC MYELOGENOUS LEUKEMIA IN BLAST CRISIS [J].
BLICK, M ;
ROMERO, P ;
TALPAZ, M ;
KURZROCK, R ;
SHTALRID, M ;
ANDERSSON, B ;
TRUJILLO, J ;
BERAN, M ;
GUTTERMAN, J .
CANCER GENETICS AND CYTOGENETICS, 1987, 27 (02) :349-356